Silver Book Fact

It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall the study finds that the value of increased longevity through these potential innovations will greatly exceed the rising costs of health care.

Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon J, Goldberg R, Dash Y, Muralimohan G
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…